Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
AIM
AIM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest AIM ETF News Today | Earnings, Events & Price Alerts
AIM News
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
1d ago
moomoo
AIM ImmunoTech Announces Rights Offering Details
Feb 12 2026
Newsfilter
AIM ImmunoTech Launches Rights Offering for $12 Million
Feb 11 2026
Newsfilter
AIM ImmunoTech to Participate in Corporate Connect Webinar
Feb 06 2026
Newsfilter
U.S. Stocks Decline in Morning Trading
Feb 05 2026
Benzinga
Healthcare Stocks Show Weak Momentum and High Valuation
Feb 03 2026
seekingalpha
AIM ImmunoTech Plans $12 Million Rights Offering
Jan 23 2026
Newsfilter
AIM ImmunoTech Declares 1-for-1000 Stock Dividend for Shareholders
Dec 30 2025
Globenewswire
AIM ImmunoTech Declares 1-for-1000 Stock Dividend for Shareholders
Dec 30 2025
Newsfilter
Ai-Media Technologies (ASX:AIM) Shares Up 111% Over Three Years Despite 12% Quarterly Drop
Dec 29 2025
Yahoo Finance
Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer
Dec 16 2025
Newsfilter
AIM ImmunoTech Highlights Pancreatic Cancer in Latest CEO Corner Segment
Dec 10 2025
Newsfilter
AI-Media Launches ADA Compliance Initiative to Aid Government Digital Accessibility
Dec 02 2025
Globenewswire
AIM ImmunoTech Announces Q3 2025 Financial Results and Ongoing Advancements in Pipeline with Emphasis on Pancreatic Cancer Clinical Initiatives
Nov 18 2025
Newsfilter
AIM ImmunoTech Unveils New UPMC Abstract on Finished Clinical Trial Highlighting Ampligen's Synergistic Effects in Treating Advanced Recurrent Ovarian Cancer
Nov 10 2025
Newsfilter
AIM ImmunoTech Set to Participate in the 2025 Maxim Growth Summit
Oct 20 2025
Newsfilter
Show More News
